We previously reported that T2DM patients have higher plasma glucagon levels than healthy subjects, and proposed that glucagon could become a diagnostic marker and a new therapeutic target for T2DM [37,38]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.